156 related articles for article (PubMed ID: 7559256)
1. Progress in antisense therapeutics.
Crooke ST
Hematol Pathol; 1995; 9(2):59-72. PubMed ID: 7559256
[TBL] [Abstract][Full Text] [Related]
2. Antisense strategies for oncogene inactivation.
Stein CA; Benimetskaya L; Mani S
Semin Oncol; 2005 Dec; 32(6):563-72. PubMed ID: 16338422
[TBL] [Abstract][Full Text] [Related]
3. Progress in antisense therapeutics discovery and development.
Crooke ST
Ciba Found Symp; 1997; 209():158-64; discussion 164-8. PubMed ID: 9383575
[TBL] [Abstract][Full Text] [Related]
4. Crohn's trial shows the pros of antisense.
Robertson D
Nat Biotechnol; 1997 Mar; 15(3):209. PubMed ID: 9062911
[No Abstract] [Full Text] [Related]
5. Antisense drug discovery and development.
Yamamoto T; Nakatani M; Narukawa K; Obika S
Future Med Chem; 2011 Mar; 3(3):339-65. PubMed ID: 21446846
[TBL] [Abstract][Full Text] [Related]
6. Antisense therapeutics.
Agrawal S; Zhao Q
Curr Opin Chem Biol; 1998 Aug; 2(4):519-28. PubMed ID: 9736926
[TBL] [Abstract][Full Text] [Related]
7. Synthetic oligonucleotides: the development of antisense therapeutics.
Monteith DK; Levin AA
Toxicol Pathol; 1999; 27(1):8-13. PubMed ID: 10367666
[TBL] [Abstract][Full Text] [Related]
8. Perspectives on antisense therapy for the prevention of restenosis.
Kipshidze N; Moses J; Shankar LR; Leon M
Curr Opin Mol Ther; 2001 Jun; 3(3):265-77. PubMed ID: 11497351
[TBL] [Abstract][Full Text] [Related]
9. Drug properties of second-generation antisense oligonucleotides: how do they measure up to their predecessors?
Henry SP; Geary RS; Yu R; Levin AA
Curr Opin Investig Drugs; 2001 Oct; 2(10):1444-9. PubMed ID: 11890363
[TBL] [Abstract][Full Text] [Related]
10. Molecular and pharmacokinetic properties associated with the therapeutics of bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin.
Lopes de Menezes DE; Hudon N; McIntosh N; Mayer LD
Clin Cancer Res; 2000 Jul; 6(7):2891-902. PubMed ID: 10914739
[TBL] [Abstract][Full Text] [Related]
11. Antisense oligonucleotide-based therapeutics for cancer.
Dean NM; Bennett CF
Oncogene; 2003 Dec; 22(56):9087-96. PubMed ID: 14663487
[TBL] [Abstract][Full Text] [Related]
12. Progress in antisense oligonucleotide therapeutics.
Crooke ST; Bennett CF
Annu Rev Pharmacol Toxicol; 1996; 36():107-29. PubMed ID: 8725384
[TBL] [Abstract][Full Text] [Related]
13. The therapeutic potential of antisense oligonucleotides.
Sharma HW; Narayanan R
Bioessays; 1995 Dec; 17(12):1055-63. PubMed ID: 8634067
[TBL] [Abstract][Full Text] [Related]
14. Development of siRNA for therapeutics: efficient synthesis of phosphorothioate RNA utilizing phenylacetyl disulfide (PADS).
Ravikumar VT; Andrade M; Carty RL; Dan A; Barone S
Bioorg Med Chem Lett; 2006 May; 16(9):2513-7. PubMed ID: 16481168
[TBL] [Abstract][Full Text] [Related]
15. [Antisense oligonucleotides: a new therapeutic approach].
Guinot P; Temsamani J
Pathol Biol (Paris); 1998 May; 46(5):347-54. PubMed ID: 9769897
[TBL] [Abstract][Full Text] [Related]
16. Antisense oligonucleotides as therapeutics for malignant diseases.
Ho PT; Parkinson DR
Semin Oncol; 1997 Apr; 24(2):187-202. PubMed ID: 9129689
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic potential of antisense nucleic acid molecules.
Opalinska JB; Gewirtz AM
Sci STKE; 2003 Oct; 2003(206):pe47. PubMed ID: 14583589
[TBL] [Abstract][Full Text] [Related]
18. Progress in antisense technology.
Crooke ST
Annu Rev Med; 2004; 55():61-95. PubMed ID: 14746510
[TBL] [Abstract][Full Text] [Related]
19. Antisense oligonucleotides in lung cancer.
Pujol JL; Jacot W
Suppl Tumori; 2002; 1(4):S50-1. PubMed ID: 12415820
[No Abstract] [Full Text] [Related]
20. Targeting Bcl-2 protein expression in solid tumors and hematologic malignancies with antisense oligonucleotides.
Tolcher AW
Clin Adv Hematol Oncol; 2005 Aug; 3(8):635-42, 662. PubMed ID: 16167050
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
